Canada Von Willebrand Disease (VWD) Therapies Market Size, Share & Industry Analysis, By Product (Humate P, Wilate and Others), By Indication (Type 1, Type 2, Type 3 and Others), By Use Case (On-demand, Peri-Op and Prophylaxis), By End User (Hospitals & ASCs, Specialty Clinics and Others), and Forecasts, 2025-2032

The Canada Von Willebrand disease (VWD) therapies market size was valued at USD 12.3 million in 2024. The market is projected to grow from USD 14.1 million in 2025 to USD 19.6 million by 2032, exhibiting a CAGR of 4.79% during the forecast period.

The market is growing steadily owing to improved diagnosis rates, expanded indications for prophylaxis in severe VWD, and increasing access to specialty hemophilia treatment centers across the country. Additionally, continuous efforts undertaken by Canadian Blood Services (CBS), and Héma‑Québec to maintain the supply of products also accelerates the market growth.

Furthermore, many key industry players, including Grifols S.A, Octapharma AG, and others are focusing on strategic initiatives to maintain their competitive edge.

MARKET DYNAMICS

MARKET DRIVERS:

Improved Diagnostic Rate and Awareness to Drive Market Growth

One of the key factors driving the Canada Von Willebrand disease (VWD) therapies market growth is improved diagnostic rate coupled with increasing awareness among population. With the supportive clinical guidelines, an increasing number of patients are correctly screened, referred and classified by type and severity, in turn growing the number eligible individuals for plasma-derived VWF therapy in on-demand, peri-operative and prophylaxis settings. Additionally, surging number of awareness and educational campaigns, encourages individuals to get tested, thereby increasing the patient pool. All these factors collectively drive the market growth.

• For instance, the Canadian Hemophilia Society (CHS) is actively involved in running campaigns to improve the understanding, diagnosis, and management of Von Willebrand Disease (VWD).

MARKET RESTRAINTS:

High Treatment Costs and Funding Barriers to Limit Market Expansion

High treatment costs and funding barriers act as a restraint for the market as vwf concentrate are among the most expensive drug classes funded through public blood programs. Although patients do not pay directly at the point of care, provincial agencies and hospital budgets face substantial financial pressure as they must absorb the high per-patient annual cost of on-demand therapy, severe peri-operative coverage, and especially long-term prophylaxis. Such funding barriers can slow market growth by delaying product uptake, limiting choice at the treatment-centre level, and reinforcing reliance on existing products.

• INESSS recommended against listing Alphanate for VWD on the provincial blood products list, citing limited added value and cost concerns compared with existing options.

MARKET OPPORTUNITIES:

Growth in Prophylactic Use for Severe VWD Offers Significant Growth Opportunities

Traditionally, different Canadian patients with severe Type 3 or high-bleeding-burden Type 2 VWD were treated mainly on-demand, limiting overall von willebrand factor consumption despite significant morbidity. However, over the years, clinicians and payers are increasingly willing to consider long-term regimens for the most severe cases, which significantly increases per-patient annual use of VWF therapies. This has created opportunity for the operating players to fulfill growing industry needs.

• For instance, Wilate is indicated for routine prophylaxis in adults and children aged 6 years and older with von Willebrand disease (VWD).

MARKET CHALLENGES:

Plasma Supply and Manufacturing Constraints Pose Significant Challenge for Market

Plasma supply and manufacturing constraints pose significant challenges to the market growth. This is owing to dependence of all plasma-derived VWF products on a stable, high-quality plasma supply and complex fractionation capacity. Canada heavily relies on plasma sourced and fractionated outside the country especially the U.S. Thus, supply chain pressure on global plasma supply or manufacturing capacity hamper the market growth in Canada.

• For instance, according to a study published in National Center for Biotechnology Information (NCBI) in September 2023, Canada highly depends on suppliers from other countries, mainly the U.S. to meet the growing plasma demand.

CANADA VON WILLEBRAND DISEASE THERAPIES MARKET TRENDS:

Integration of Home Therapy and Self-Administration Is a Significant Trend Observed in Market

A key emerging trend in the market is integration of home therapy and self-administration. The market is witnessing a shift from hospital-only infusions to patient-managed treatment at home. This shift reduces emergency visits and inpatient stays, while increasing comfort with regular factor use and supporting broader adoption of prophylaxis in severe VWD.

• For instance, Providence Health Care offers home coagulation factor infusion program in Canada.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Wider Availability of Humate P to Propel Segmental Growth

Based on the product, the market is divided into Humate P, Wilate, and Others.

To know how our report can help streamline your business, Speak to Analyst

The Humate P segment is expected to dominate the market during the forecast period with largest market share. The dominance of the segment is attributed wide availability of this product on the Canadian Blood Services (CBS) and Héma-Québec formularies. Additionally, increasing usage of this product by healthcare professional also propels the segment growth.

Moreover, the Wilate segment is expected to grow at a CAGR of 7.85% during the forecast period.

By Indication

High Number of Approved Products for Type 3 to Drive the Segmental Growth

Based on the Indication, the market is segmented into type 1, type 2, type 3, and others.

In 2024, the type 3 segment held the largest Canada von Willebrand disease (VWD) therapies market share based on indication. The segment's dominance can be attributed to high consumption of VWF per patient than any other type. Additionally, long term treatment requirement for these patients further drives the segment growth. Furthermore, the segment is set to hold 53.0% share in 2025.

• For instance, Wilate is used for type 3 disease.

Additionally, the market for type 2 is projected to grow at a CAGR of 4.06% during the study period.

By Use case

Increasing Consumption for Immediate Clinical Need Drives On-Demand Segment Growth

Based on use case, the market is divided into on-demand, peri-op, and prophylaxis.

In 2024, on the basis of use case, the on-demand segment captured the largest market share. Furthermore, the on-demand segment is set to hold a 51.1% share in 2025. Key factors supporting this leading position include its increasing consumption for immediate clinical need, for acute spontaneous or trauma-related bleeds and emergency situations.

• For instance, Humate-P can be used on-demand to treat active bleeding episodes in adults with von Willebrand disease (VWD) or hemophilia A.

In addition, the prophylaxis segment is projected to grow at a CAGR of 13.04% during the study period.

By End User

High Number of Patient Visits to Drive the Segmental Growth of Hospitals & ASCs

Based on end user, the market is segmented into specialty clinics, hospitals & ASCs, and others.

In 2024, based on end user, the market was dominated by hospitals & ASCs with the leading share. Furthermore, the hospitals & ASCs segment is set to hold a 65.4% share in 2025. The can be attributed to high-intensity use cases for VWD therapies, hospital-centric care model, and increasing patient flow in these settings. Additionally, patient support programs offered by several hospitals in Canada further support the segment dominance.

• For instance, the Adult Bleeding Disorders Program of BC is based at St. Paul’s Hospital (Providence Health Care) and provides comprehensive care for people with inherited bleeding disorders, including Von Willebrand Disease.

In addition, the specialty clinics segment is projected to grow at a CAGR of 6.46% during the study period.

COMPETITIVE LANDSCAPE

Key Industry Players:

Strategic Collaborations by Key Players to Strengthen their Market Positions

The Canada VWD therapies market is highly consolidated, with prominent players such as Grifols, S.A., CSL Behring LLC., and Octapharma AG capturing the majority of the market share in 2025. These companies have leading position in the market owing to factors such as collaboration with Canadian Blood Services (CBS) and Héma-Québec, and strong plasma collection network in the country.

• For instance, in September 2022, Grifols and Canadian Blood Services signed a long-term collaboration agreement to accelerate self-sufficiency in plasma-derived medicines for Canada.

LIST OF KEY CANADA VON WILLEBRAND DISEASE THERAPIES MARKET PROFILED:

• Grifols, S.A. (Spain)
• CSL Behring LLC. (U.S.)
• Octapharma AG (Switzerland)

KEY INDUSTRY DEVELOPMENTS:

• February 2024: Octapharma Canada announced the approval of Wilate in Canada for se in prophylaxis treatment of Von Willebrand Disease (VWD) in adults and pediatric patients aged 6 and older with any type of VWD.
• June 2023: Octapharma AG presented new data related to bleeding disorders including von Willebrand disease at the 31st Congress of International Society on Thrombosis and Haemostasis (ISTH) held in Montréal, Canada.
• September 2022: The Canadian Hemophilia Society (CHS) announced strong support to Canadian Blood Services’ plasma initiative.

REPORT COVERAGE

The Canada VWD therapies market analysis provides a detailed study of the market size & forecast by all the market segments included in the report. The report also provides insights into market dynamics and trends expected to drive the market during the forecast period. The Canada VWD therapies market report also comprises key aspects, such as an overview of technological advancements, product launches, insights on strategic partnerships, mergers & acquisitions, and key industry developments in Canada. The market forecast also provides a detailed competitive landscape, including market share and profiles of major industry players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation